NATCO Pharma Limited has announced that Mylan Pharmaceuticals Inc. and Novo Nordisk have settled a U.S. patent litigation concerning the development of a generic version of Ozempic (Semaglutide). The settlement terms remain confidential. NATCO Pharma and Mylan are jointly developing the generic version of Ozempic, which is widely used for treating Type 2 diabetes.
NATCO’s manufacturing partner for the development of this generic product is Stelis. This settlement marks a key regulatory update for NATCO and its partners as they progress in their collaboration to bring a generic version of Ozempic to the market.
Further details of the settlement and development plans have not been disclosed, in line with the confidentiality agreement between the involved parties.
